Following the FDA’s September 2025 announcement that leucovorin could treat cerebral folate deficiency—a rare condition with some autism-like symptoms—prescriptions for the drug surged across the United States, according to Gram Research analysis. The increase occurred despite leucovorin only being approved for an extremely rare neurological condition, suggesting that media coverage and political attention influenced prescribing decisions more than scientific evidence about autism treatment.
When the FDA announced in September 2025 that leucovorin (a form of vitamin B9) could treat a rare brain condition related to autism, prescriptions for the drug jumped dramatically across the United States. According to Gram Research analysis, this spike happened after media coverage and a White House announcement, even though leucovorin was only approved for a very specific condition affecting a tiny number of people. Researchers studied how much prescribing patterns changed during this period of intense public attention, raising important questions about whether hype influences medical decisions.
Key Statistics
A 2026 research article published in Pediatrics found that leucovorin prescriptions increased significantly following the FDA’s September 2025 announcement and preceding media coverage in February 2025, despite the drug only being approved for the extremely rare condition cerebral folate deficiency.
The FDA’s announcement about leucovorin for cerebral folate deficiency was accompanied by a White House press conference and national media reports, which preceded a measurable increase in prescriptions across the United States healthcare system.
Leucovorin, also known as folinic acid or vitamin B9, was originally FDA-approved to reduce side effects from cancer treatments like methotrexate, but its label was expanded in September 2025 to include treating cerebral folate deficiency, a condition that shares some symptoms with autism spectrum disorder.
The Quick Take
- What they studied: How many prescriptions for leucovorin were written before and after the FDA’s September 2025 announcement about its potential use for autism-related conditions
- Who participated: The study examined prescription data across the entire United States healthcare system during the period of heightened media coverage and political attention around leucovorin
- Key finding: Leucovorin prescriptions increased significantly following the FDA announcement and media coverage, despite the drug only being approved for an extremely rare neurological condition called cerebral folate deficiency
- What it means for you: Parents and doctors should be cautious about using leucovorin for autism based on hype alone. The drug is only FDA-approved for a very specific, rare condition. Talk to your doctor about whether it’s appropriate for your situation, and don’t assume media coverage means a treatment is proven to work for autism.
The Research Details
Researchers tracked prescription data for leucovorin across the United States before and after September 2025, when the FDA made its announcement about the drug’s expanded use. They looked at how media coverage in February 2025 and the White House press conference in September 2025 affected how often doctors prescribed leucovorin. By comparing prescription numbers before and after these events, they could see whether public attention changed prescribing patterns.
This type of study is called a descriptive analysis because it describes what happened to prescription rates during a specific time period. The researchers weren’t testing whether leucovorin actually works for autism—they were simply measuring whether doctors prescribed it more often after the announcement.
This research matters because it shows how media coverage and political announcements can influence medical decisions, even when the scientific evidence is still limited. Understanding these patterns helps doctors and patients make better decisions based on actual evidence rather than hype. It also highlights the gap between what’s approved for a rare condition and how it might be used off-label for other conditions.
This study provides real-world data about prescribing patterns, which is valuable information. However, the study doesn’t tell us whether leucovorin actually helps people with autism—it only shows that prescriptions increased. The study was published in Pediatrics, a respected medical journal. Readers should understand that this is observational data showing what happened, not proof that the treatment works.
What the Results Show
Following the FDA’s announcement in September 2025 and the preceding media coverage in February 2025, prescriptions for leucovorin increased across the United States. This increase occurred even though the FDA’s approval was specifically for cerebral folate deficiency, an extremely rare neurological condition that affects only a small number of people.
The timing of the prescription increases suggests that media attention and the White House press conference had a significant impact on prescribing decisions. Doctors began writing more prescriptions for leucovorin during the period of heightened public attention, indicating that news coverage influenced clinical practice.
This pattern raises important questions about how medical decisions are made. When a drug gets attention in the media and from government officials, doctors may prescribe it more often, even if the scientific evidence for a particular use is still being studied. The study demonstrates a real-world example of how non-scientific factors can influence medical practice.
The research highlights the difference between what a drug is officially approved for and how it might actually be used in practice. Leucovorin was approved by the FDA specifically for treating cerebral folate deficiency, but the increased prescriptions suggest it was being used more broadly for autism spectrum disorder. This off-label use (using a drug for purposes beyond its official approval) is legal but should be based on solid evidence.
This study fits into a broader pattern of research showing that media coverage and political attention can influence medical practice. Previous studies have shown that when conditions get media attention, diagnosis and treatment rates often increase. This research adds to that body of evidence by showing a specific, measurable example with leucovorin.
The study doesn’t tell us whether leucovorin actually helps people with autism. It only shows that prescriptions increased after the announcement. The study also doesn’t explain why individual doctors prescribed leucovorin—whether they believed in the treatment, responded to patient requests, or were influenced by media coverage. Additionally, the study doesn’t provide information about whether the increased prescriptions led to better outcomes for patients.
The Bottom Line
If you or your child has autism, talk to your doctor about whether leucovorin might be appropriate. The drug is only FDA-approved for cerebral folate deficiency, which is extremely rare. Any use for autism would be off-label and should be based on your individual situation and your doctor’s professional judgment, not on media headlines. Ask your doctor about the evidence supporting its use and what benefits and risks to expect. Confidence level: Moderate—based on the principle that medical decisions should be individualized and evidence-based.
Parents of children with autism, people with autism, and healthcare providers should pay attention to this research. It’s a reminder to be cautious about new treatments that get a lot of media attention. People with cerebral folate deficiency should work with their doctors about appropriate treatment. The general public should understand how media coverage can influence medical decisions.
If leucovorin were appropriate for your situation, you wouldn’t see benefits overnight. Any effects would likely develop gradually over weeks to months. However, since the drug is only officially approved for a rare condition, most people with autism shouldn’t expect it to be a treatment option without strong evidence and medical supervision.
Frequently Asked Questions
Is leucovorin approved by the FDA for treating autism?
Leucovorin is not FDA-approved for autism. The FDA approved it in September 2025 for cerebral folate deficiency, an extremely rare neurological condition with some autism-like symptoms. Any use for autism would be off-label and should only be considered under medical supervision.
Why did leucovorin prescriptions increase after the FDA announcement?
Research shows prescriptions increased following media coverage and a White House press conference, suggesting that public attention influenced prescribing decisions. However, the study doesn’t prove the drug works for autism—it only shows that doctors prescribed it more often during the period of heightened attention.
Should I ask my doctor about leucovorin for my child’s autism?
You can discuss it with your doctor, but understand that it’s not officially approved for autism. Your doctor can explain whether your child might have cerebral folate deficiency or whether off-label use might be appropriate based on individual circumstances and available evidence.
What is cerebral folate deficiency and how does it relate to autism?
Cerebral folate deficiency is an extremely rare neurological condition affecting the brain’s folate levels. It shares some symptoms with autism spectrum disorder, which is why the FDA approved leucovorin for this condition. However, most people with autism don’t have cerebral folate deficiency.
Does media coverage of medical treatments affect how doctors prescribe medications?
This study suggests yes—prescriptions for leucovorin increased after media coverage and political announcements. This demonstrates that non-scientific factors can influence medical decisions, which is why it’s important to ask your doctor about evidence supporting any recommended treatment.
Want to Apply This Research?
- If prescribed leucovorin by your doctor, track any changes in specific autism-related symptoms (like social interaction, communication, or repetitive behaviors) weekly using a simple 1-10 scale. Note the date, symptom, and rating to share with your healthcare provider.
- If your doctor recommends leucovorin, set a daily reminder to take it at the same time each day. Use the app to log when you take it and any side effects you notice, creating a clear record for your doctor’s next appointment.
- Create a monthly summary of symptom changes and medication adherence. Share these reports with your healthcare provider every 4-6 weeks to determine if the treatment is working and whether to continue, adjust, or stop it.
This article summarizes research about leucovorin prescribing patterns and should not be considered medical advice. Leucovorin is only FDA-approved for treating cerebral folate deficiency and reducing side effects from certain cancer medications. Any use for autism spectrum disorder would be off-label. Parents and individuals with autism should consult with qualified healthcare providers before starting, stopping, or changing any medication. This research describes prescribing patterns, not treatment effectiveness. Individual medical decisions should be based on personal circumstances, medical history, and professional medical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.